四环生物(000518) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was ¥56,398,850.85, a decrease of 1.08% compared to ¥57,013,482.58 in the same period last year[5] - The net loss attributable to shareholders was ¥2,967,209.29, an improvement of 84.35% from a loss of ¥18,959,108.45 in the previous year[5] - The basic and diluted earnings per share improved by 84.24%, from -¥0.0184 to -¥0.0029[5] - Net profit for the first quarter was a loss of ¥3,230,218.16, compared to a loss of ¥21,122,207.95 in the same period last year, representing an improvement of approximately 84.7%[19] - Operating profit improved to a loss of ¥4,048,302.24 from a loss of ¥21,889,366.63, indicating a significant reduction in losses[18] Cash Flow and Liquidity - The net cash flow from operating activities increased by 77.44% to ¥5,412,924.97, up from ¥3,050,580.73 in the same period last year[5] - Cash and cash equivalents at the end of Q1 2024 were CNY 16,499,359.61, down from CNY 18,927,001.92 at the beginning of the period, representing a decrease of 12.76%[13] - The cash and cash equivalents at the end of the period were ¥12,697,043.58, down from ¥25,137,867.09, indicating a decrease of approximately 49.5%[22] Assets and Liabilities - Total assets at the end of the reporting period were ¥653,491,489.39, a decrease of 1.13% from ¥660,975,034.49 at the end of the previous year[5] - Total liabilities decreased to CNY 143,941,215.12 from CNY 148,194,542.06, a reduction of 2.52%[15] - The company's total equity decreased to CNY 509,550,274.27 from CNY 512,780,492.43, a decline of 0.45%[15] - Non-current assets totaled CNY 147,465,828.09, down from CNY 151,595,031.95, a decrease of 2.73%[14] Expenses and Cost Management - The company reported a significant reduction in sales expenses by 50.38%, from ¥35,696,459.01 to ¥17,711,806.65[9] - Total operating costs decreased to ¥56,979,130.03 from ¥74,401,151.38, a reduction of approximately 23.4% year-over-year[18] - Research and development expenses were ¥6,903,522.01, slightly down from ¥7,340,182.16, reflecting a focus on cost management[18] Investment and Income - Investment income increased by 115.94%, from -¥218,024.90 to ¥34,744.67, indicating a turnaround in joint ventures[9] - The company reported an investment loss of ¥34,744.67, a significant recovery from a loss of ¥218,024.90 in the previous year[18] Shareholder Information - The number of ordinary shareholders at the end of the reporting period was 109,093, with the top ten shareholders holding significant stakes[10] Government Support - The company received government subsidies amounting to ¥37,368.06 during the reporting period[6] Other Information - The company has not reported any new product launches or significant market expansion strategies during this quarter[12] - The first quarter report has not been audited[24] - The new accounting standards will be implemented starting in 2024[23]